Effect of High Fat Diet on Muscle Metabolism
1 other identifier
interventional
11
1 country
1
Brief Summary
Skeletal muscle burns a significant amount of the fat and sugar that circulates in the blood stream. Ideally, when sugar is elevated in the blood stream, the muscle will either use it to make new energy or store it for later use. Likewise, for fatty acids. Skeletal muscle of obese and diabetic humans has been shown to inadequately use either sugar or fatty acids when they increase in the blood stream, and this has been termed metabolic inflexibility. The cause of metabolic inflexibility is not known, but it is believed that eating more fat than the body needs for energy may be a contributing factor. Metabolic inflexibility in skeletal muscle is bad because if the muscle does not use the sugar or fat, it will be stored elsewhere in the body and potentially lead to obesity and the resistance to insulin. The investigators have performed a research study with nonobese, healthy humans during which we fed them a high fat diet for 5 days. Interesting, only 5 days of a high fat diet is sufficient to cause the skeletal muscle to become metabolically inflexible just like that observed in obese and diabetic humans. The investigators are proposing addition studies to feed healthy humans a high fat diet for 5 days in effort to better understand what causes metabolic flexibility. The investigators are speculating that a high fat diet causes the intestines to release a substance called endotoxin that causes muscle to become metabolically inflexible. The investigators will test this notion in our proposed studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes
Started Jan 2013
Longer than P75 for not_applicable diabetes
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2013
CompletedFirst Submitted
Initial submission to the registry
December 22, 2014
CompletedFirst Posted
Study publicly available on registry
December 31, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
March 9, 2018
CompletedApril 13, 2026
April 1, 2026
4.9 years
December 22, 2014
April 8, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Metabolic Flexibility measured ex vivo in skeletal muscle using radio labeled carbon isotopes
Assess substrate handling ex vivo in skeletal muscle using radio labeled isotopes pre and post high fat diet
1 day
Secondary Outcomes (1)
Intestinal Permeability using a 4 sugar probe test and mass spectrometry
24 hours
Study Arms (1)
High Saturated Fat Diet
EXPERIMENTALSubjects will receive a high fat diet for 5 day following a 2 week lead in diet. Measurements will be made pre-post high fat diet
Interventions
Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to "lead-in" to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study.
Eligibility Criteria
You may qualify if:
- Males, age 18-40 years; BMI between 20 and 30 kg/m2. Weight stable for previous 6 months (± 2.0kg).
- Sedentary to recreationally active (≤ 3 days, 20 min/day of walking type exercise, no planned exercise other than leisure walking for transportation purposes).
- Verbal and written informed consent
- non-smoking
- Approved for participation by Medical Director (Jose Rivero, M.D.)
You may not qualify if:
- \. Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease
- \. Family history of diabetes
- \. BMI \> 30 kg/m2, blood pressure \> 140/90 mmHg or antihypertensive medications, fasting glucose \> 100 mg/dl, LDL cholesterol \> 130 mg/dl, total cholesterol \> 200 mg/dl, triglycerides \> 250 mg/dl.
- \. Verbal and written informed consent
- \. Smoking, alcohol consumption \> 2 servings/d, or taking medications (including but not limited to statins or other drugs with anti-inflammatory actions) or antioxidant vitamins or supplements, or know to affect carbohydrate or lipid metabolism.
- \. Total daily dietary fat consumption ≥ 35% and/or saturated fat consumption of ≥ 15%.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kevin Davylead
- American Diabetes Associationcollaborator
Study Sites (1)
Virginia Polytechnic and State University
Blacksburg, Virginia, 24061, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kevin P Davy, PhD
Virginia Polytechnic Institute and State University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 22, 2014
First Posted
December 31, 2014
Study Start
January 1, 2013
Primary Completion
December 1, 2017
Study Completion
March 9, 2018
Last Updated
April 13, 2026
Record last verified: 2026-04